Image
|
Figure Caption
FIGURE 1
Addressing HSCT limitations. Clinical (established) and preclinical (theoretical) advances are informing treatment options for circumventing current HSCT limitation including, A, post‐transplant infection, B, low HSC donor supply, C, inflammation, and D, graft‐vs‐host disease (GVHD). Check mark indicates an established treatment in humans, while open circles signify ongoing preclinical research. BMSC, bone marrow stromal cell; HLA, human leukocyte antigen; HSC, hematopoietic stem cell; HSCT, hematopoietic stem cell transplantation; MPP, multipotent progenitors; ST‐HSC, short‐term HSC
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Stem Cells Transl. Med.